Prostate biomarkers with reference to body mass index and duration of prostate cancer.
OBJECTIVE
This study was performed to assess prostate biomarkers with reference to body mass index and duration of prostate cancer.


METHODS
A hospital based retrospective study was undertaken using data retrieved from the register maintained in the Department of Biochemistry of Manipal Teaching Hospital, Pokhara, Nepal between 1st January, 2009 and 28th February, 2012. Biomarkers studied were prostate specific antigen (PSA), acid phosphatase (ACP) and prostatic acid phosphatase (PAP), alkaline phosphatase (ALP) and gamma glutamyl transpeptidase (γGT). Demographic data including age, duration of disease, body weight, height and body mass index (BMI) were also collected. Duration of disease was categorized into three groups: <1 year, 1-2 years and >2 years. Similarly, BMI (kg/m2) was categorized into three groups: <23 kg/m2, 23-25 kg/ m2 and >25 kg/m2. Descriptive statistics and testing of hypothesis were used for the analysis using EPI INFO and SPSS 16 software.


RESULTS
Out of 57 prostate cancers, serum level of PSA, ACP and PAP were increased above the cut-off point in 50 (87.5%), 30 (52.63%) and 40 (70.18%) respectively. Serum levels of PSA, ACP and PAP significantly declined with the duration of disease after diagnosis. We observed significant and inverse relation between PSA and BMI. Similar non-signficiant tendencies were apparent for ACP and PAP.


CONCLUSIONS
Decreasing levels of prostate biomarkers were found with the duration of prostate cancer and with increased BMI. Out of prostate biomarkers, PSA was found to be significantly decreased with the duration of disease and BMI.
Department of Biochemistry, Manipal College of Medical Sciences, Pokhara, Nepal. bibekclb@yahoo.com
Bibek
B
Poudel
Ankush
A
Mittal
Rojeet
R
Shrestha
Ashwini Kumar
AK
Nepal
Pramod Shanker
PS
Shukla
D014408:Biomarkers, Tumor / Q000378:metabolism*; D015992:Body Mass Index; D016022:Case-Control Studies; D018450:Disease Progression; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008403:Mass Screening; D011379:Prognosis; D011467:Prostate / Q000378:metabolism*; D011471:Prostatic Neoplasms / Q000175:diagnosis / Q000378:metabolism*; D012189:Retrospective Studies; D013997:Time Factors
D014408:Biomarkers, Tumor